Tags : Collaborate

Pharma

Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib

Shots: The companies collaborated to assess Turning Point’s elzovantinib (TPX-0022) in combination with EQRx’s aumolertinib in patients with EGFR mutant MET-amplified advanced NSCLC Turning Point will sponsor and conduct a P-Ib/II clinical trial to evaluate the safety, tolerability and preliminary efficacy of the combination regimen and will assume all costs associated with the trial whereas […]Read More

Pharma

BridgeBio Collaborates with Helsinn to Co- Develop and Commercialize Infigratinib

Shots: BridgeBio to receive ~$2.45B+ including ~$100M in up front, regulatory and commercial milestones along with royalties on net sales of Infigratinib from Helsinn Group. The agreement is expected to close in Q2’21 Helsinn to co-commercialize infigratinib in oncology and other indications except for skeletal dysplasia indications in the US and will equally share profits […]Read More

Biosimilars

Samsung Bioepis and Yuhan Collaborate for the Commercialization of Adalloce

Shots: Samsung Bioepis enter into a marketing collaboration with Yuhan Corporation for the domestic sale of Adalloce in Korea to treat RA, AS, and CD Additionally, Samsung Bioepis is conducting domestic sales of Etoloce (biosimilar, enbrel) and Remaloce (biosimilar, Remicade), which have been previously released, through Yuhan Corporation Based on the contract, the cooperation between […]Read More

Biotech

UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development

Shots: The collaboration will merge Microsoft’s computational services, cloud and AI with UCB’s drug discovery and development capabilities The companies intend to discover and develop medicines for people living with severe diseases in immunology and neurology. The collaboration follows UCB and Microsoft’s collaboration around COVID-19 Microsoft will provide AI technology and applied scientists to work […]Read More

Biotech

Sanofi Collaborates with i2O Therapeutics to Evaluate Oral i2O Therapeutics

Shots: The companies collaborated to investigate oral delivery of Sanofi’s Nanobody based medicines, which are currently available in IV & SC formulations The collaboration will advance the formulation of therapies that are traditionally limited to injections. Nanobodies are the therapeutic proteins based on camelid-derived immunoglobulin single variable domains & have potential to treat multiple diseases […]Read More